133 related articles for article (PubMed ID: 8685221)
21. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma.
Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ
Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242
[TBL] [Abstract][Full Text] [Related]
22. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study.
Hamilton TE; Green DM; Perlman EJ; Argani P; Grundy P; Ritchey ML; Shamberger RC
J Pediatr Surg; 2006 Oct; 41(10):1641-4. PubMed ID: 17011261
[TBL] [Abstract][Full Text] [Related]
23. Extracellular matrix and epithelial differentiation of Wilms' tumor.
Sariola H; Ekblom P; Rapola J; Vaheri A; Timpl R
Am J Pathol; 1985 Jan; 118(1):96-107. PubMed ID: 2981473
[TBL] [Abstract][Full Text] [Related]
24. Anaplastic sarcoma of the kidney: a clinicopathologic study of 20 cases of a new entity with polyphenotypic features.
Vujanić GM; Kelsey A; Perlman EJ; Sandstedt B; Beckwith JB
Am J Surg Pathol; 2007 Oct; 31(10):1459-68. PubMed ID: 17895746
[TBL] [Abstract][Full Text] [Related]
25. Isolation of kidney complementary DNAs down-expressed in Wilms' tumor by a subtractive hybridization approach.
Austruy E; Cohen-Salmon M; Antignac C; Béroud C; Henry I; Nguyen VC; Brugières L; Junien C; Jeanpierre C
Cancer Res; 1993 Jun; 53(12):2888-94. PubMed ID: 7916648
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors.
Granzen B; Efferth T; Keller U; Beniers AJ; Mertens R; Jakse G; Füzesi L
Anticancer Res; 2001; 21(1B):771-6. PubMed ID: 11299842
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
28. p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.
Overall ML; Spencer J; Bakker M; Dziadek M; Smith PJ
Genes Chromosomes Cancer; 1996 Sep; 17(1):56-9. PubMed ID: 8889507
[TBL] [Abstract][Full Text] [Related]
29. p53 immunopositivity in histologically favorable Wilms tumor is not related to stage at presentation or to biological aggression.
D'Angelo MF; Kausik SJ; Sebo TJ; Rathbun SR; Kramer SA; Husmann DA
J Urol; 2003 May; 169(5):1815-7. PubMed ID: 12686851
[TBL] [Abstract][Full Text] [Related]
30. Expression and localization of HGF and met in Wilms' tumours.
Alami J; Williams BR; Yeger H
J Pathol; 2002 Jan; 196(1):76-84. PubMed ID: 11748645
[TBL] [Abstract][Full Text] [Related]
31. [Anaplastic type of Wilms' tumour].
Vujanić GM; Aleksandrović S
Srp Arh Celok Lek; 1990; 118(9-10):353-6. PubMed ID: 1966350
[TBL] [Abstract][Full Text] [Related]
32. Expression of the N-myc oncogene in Wilms' tumour and related tissues.
Shaw AP; Poirier V; Tyler S; Mott M; Berry J; Maitland NJ
Oncogene; 1988 Aug; 3(2):143-9. PubMed ID: 2842712
[TBL] [Abstract][Full Text] [Related]
33. Expression of apoptosis, cell proliferation, and drug resistance genes in pediatric Wilms' tumors.
Ramachandran C; Melnick SJ; Escalon E; Jhabvala P; Khatib Z; Alamo A; Smith S
Anticancer Res; 2000; 20(5C):3759-65. PubMed ID: 11268451
[TBL] [Abstract][Full Text] [Related]
34. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
35. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor.
Barbosa AS; Hadjiathanasiou CG; Theodoridis C; Papathanasiou A; Tar A; Merksz M; Györvári B; Sultan C; Dumas R; Jaubert F; Niaudet P; Moreira-Filho CA; Cotinot C; Fellous M
Hum Mutat; 1999; 13(2):146-53. PubMed ID: 10094551
[TBL] [Abstract][Full Text] [Related]
36. Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumours.
Lemoine NR; Hughes CM; Cowell JK
J Pathol; 1992 Oct; 168(2):237-42. PubMed ID: 1334142
[TBL] [Abstract][Full Text] [Related]
37. p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix.
Waggoner SE; Anderson SM; Luce MC; Takahashi H; Boyd J
Gynecol Oncol; 1996 Mar; 60(3):339-44. PubMed ID: 8774636
[TBL] [Abstract][Full Text] [Related]
38. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
39. Genomic changes in the WT-gene (WT1) in Wilms' tumors and their correlation with histology.
Kikuchi H; Akasaka Y; Nagai T; Umezawa A; Iri H; Kato S; Hata J
Am J Pathol; 1992 Apr; 140(4):781-6. PubMed ID: 1314024
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
